Selective Inhibition of NaV1.8 with VX-548 for Acute Pain | NEJM
WEBAug 2, 2023 · VX-548 is a potent and selective inhibitor of Na V 1.8 currents relative to other Na V channels in human dorsal-root ganglion neurons in vitro. In two phase 2 clinical trials of postoperative...
Press Release - Vertex Pharmaceuticals Newsroom
WEBDec 13, 2023 · NaV1.8 is a genetically validated target for the treatment of pain, and Vertex has previously demonstrated positive proof-of-concept results and a well-tolerated profile with VX-548 in two Phase 2 studies of acute pain following abdominoplasty and bunionectomy surgeries.
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute …
WEBApr 18, 2024 · In line with its pain portfolio serial innovation strategy, Vertex continues to advance preclinical and clinical development of additional NaV1.8 and NaV1.7 pain signal inhibitors, for use alone or in combination, in acute and neuropathic pain. The company intends to advance its next generation NaV1.8 pain signal inhibitor VX-993 oral ...
Press Release - Vertex Pharmaceuticals Newsroom
WEBJan 30, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the …
New non-opioid pain drug pushes through to pivotal trials - Nature
WEBOct 14, 2022 · Vertex is set to move a small-molecule inhibitor of voltage-gated sodium channel 1.8 (Nav1.8) into phase III trials in acute pain by the end of the year.
WEBAug 2, 2023 · We describe the preclini-cal characterization of VX-548, an oral, highly selective inhibitor of Na V1.8, and we report the results of two phase 2 trials evaluating the effi-cacy and safety of...
Vertex Announces Statistically Significant and Clinically …
WEBMar 31, 2022 · Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of medicines that have the potential to provide superior relief of acute pain without the limitations of …
Vertex’s NaV1.8 inhibitor passes phase II pain point - Nature
WEBApr 8, 2022 · Vertex’s Na V 1.8-targeted VX-548 reduced acute pain in two phase II trials — following abdominoplasty or bunionectomy surgery — paving the way for a pivotal trial of the non-opioid pain ...
Vertex’s non-opioid painkiller passes phase III tests - Nature
WEBFeb 12, 2024 · Vertex’s Na V 1.8 inhibitor VX-548 passed its phase III trials in abdominoplasty and bunionectomy, offering better pain relief than placebo to patients after these elective surgeries.
Press Release - Vertex Pharmaceuticals Newsroom
WEBJul 30, 2024 · Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of pain signal inhibitors that have the potential to provide effective relief of pain without the limitations of currently available therapies, including the addictive potential of opioids.